Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson(The University of Melbourne), Tony Kouzarides(The Gurdon Institute), George Giotopoulos(Wellcome/MRC Cambridge Stem Cell Institute), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), Wai-In Chan(University of Cambridge), Antje Dittmann(University of Zurich), Dave Lugo(GlaxoSmithKline (United Kingdom)), Samuel C. Robson(University of Portsmouth), Philip D. Jeffrey(Princeton University), Konstanze Doehner(University Hospital Ulm), Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Emma J. Roberts(GlaxoSmithKline (United Kingdom)), Olivier Mirguet(GlaxoSmithKline (France)), Carsten Hopf(Technische Hochschule Mannheim), Marcus Bantscheff(Roche (Switzerland)), Ruud Delwel(Erasmus MC Cancer Institute), Emma Gudgin(University of Cambridge), Sören Beinke(GlaxoSmithKline (United Kingdom)), Gerard Drewes(Unknown), Peter E. Soden(GlaxoSmithKline (United Kingdom)), Trevor Chapman(GlaxoSmithKline (United Kingdom)), Kevin Lee(GlaxoSmithKline (United Kingdom)), Alan K. Burnett(Cardiff University), Mikhail M. Savitski(European Molecular Biology Laboratory), Kurt R. Auger(Research Triangle Park Foundation), Carola Huthmacher
Cited by 1,521
Related Papers
Regulation of chromatin by histone modifications
|Cell Research|2011|5.9k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Mass-spectrometry-based draft of the human proteome
|Nature|2014|1.9k